Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)

Name: Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)
Creator: Andrew Blauvelt
Published: 2020-06-08T14:58:14.794Z
Keywords: Clinical Trial, Psoriasis

Blauvelt, Andrew; Papp, Kim A.; Merola, Joseph F.; Gottlieb, Alice B.; Cross, Nancy; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Griffiths, Christopher E.M.

doi:10.17632/5ry2hmc2wm.1

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)

Published: 8 June 2020| Version 1 | DOI: 10.17632/5ry2hmc2wm.1

Contributors:

,

, Maggie Wang,

,

Description

Supplemental materials for the manuscript: 'Bimekizumab for patients with moderate- to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.' Includes supplemental methods for the BE ABLE 2 phase 2b trial, patient demographics and baseline characteristics, incidence of serious treatment-emergent adverse events in the trail, patient disposition flowchart, PASI90 reponse rates over time in Week 12 PASI90 responder and non-responder subgroups, and PASI100 response rates over time in Week 12 PASI90 responders.

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)

Description

Files

Categories

Licence